405 related articles for article (PubMed ID: 1699653)
1. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
[TBL] [Abstract][Full Text] [Related]
2. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
4. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851.
Ginsberg SJ; Anderson JR; Gottlieb AJ; Bloomfield CD; Norton L; Barcos M; Holland JF
NCI Monogr; 1987; (5):77-80. PubMed ID: 2448657
[TBL] [Abstract][Full Text] [Related]
6. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
7. The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Lishner M; Slingerland J; Theresa C; Sutcliffe SB
Leuk Lymphoma; 1994 Mar; 13(1-2):131-6. PubMed ID: 7517744
[TBL] [Abstract][Full Text] [Related]
8. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
[TBL] [Abstract][Full Text] [Related]
9. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
Armitage JO
Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
[TBL] [Abstract][Full Text] [Related]
13. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
[TBL] [Abstract][Full Text] [Related]
14. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
[TBL] [Abstract][Full Text] [Related]
15. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
16. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
17. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
Cassi E; Butti C; Baldini L; Pisoni GB; Ceriani A; Confalonieri C; Scandolaro L; De Paoli A; Lombardi F; Montalbetti L
Leuk Lymphoma; 1994 Mar; 13(1-2):111-8. PubMed ID: 7517742
[TBL] [Abstract][Full Text] [Related]
18. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Kwak LW; Wilson M; Weiss LM; Doggett R; Dorfman RF; Warnke RA; Horning SJ
J Clin Oncol; 1991 Aug; 9(8):1426-31. PubMed ID: 1712837
[TBL] [Abstract][Full Text] [Related]
19. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
[TBL] [Abstract][Full Text] [Related]
20. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI
J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
